

# Post Chevron Educational Resources & Updates

The Supreme Court's decision in *Loper Bright Enters. v. Raimondo* and *Relentless, Inc. v. Department of Commerce* upended 40 years of judicial deference to administrative agencies' interpretation of the statutes they are tasked with implementing. Almost overnight, much of the regulatory framework that has defined and constrained businesses in the United States has been called into question. Regulated industries (e.g., health care, energy, medical devices, education, banking, etc.) will find both new opportunities and challenges in this shifting landscape. Polsinelli can help your company navigate the uncertainty and assess new opportunities post-Chevron.

## Publications

---

September 10, 2024

**Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn**

*Quoted, Pink Sheet Citeline Regulatory*

August 7, 2024

**Top Questions Health Care Providers Should Consider in a Post-Chevron World – A Polsinelli Round Table Discussion**

August 6, 2024

**What Challenges Will FDA Face In A Post-Chevron World?**

*Quoted, American Conference Institute*

July 29, 2024

**Challenges to LDT Final Rule Continue as Rule Goes into Effect**

July 23, 2024

**The Chevron Doctrine: Part II—Congress's Reaction to the Repeal and the Legislative Process**

July 10, 2024

**Provider Reimbursement Disputes Go Back to 1984 Following Supreme Court's Regulatory Reset**

May 2, 2024

**The Chevron Doctrine: Part I**